Gilead Sciences, Inc. reports the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Harvoni (ledipasvir 90 mg/sofosbuvir 400 mg), a once-daily single tablet regimen for the treatment of chronic hepatitis C genotype 1 infection in adults. Harvoni combines the NS5A inhibitor, ledipasvir, with the nucleotide analog polymerase inhibitor sofosbuvir, approved by the MHLW under the trade name Sovaldi in March 2015. Harvoni is indicated for the suppression of viremia in patients with genotype 1 chronic hepatitis C virus (HCV) infection with or without compensated cirrhosis, with a treatment duration of 12 weeks.

Source: Gilead Sciences /p>